An MDS xenograft model utilizing a patient-derived cell line.
作者信息
Rhyasen G W, Wunderlich M, Tohyama K, Garcia-Manero G, Mulloy J C, Starczynowski D T
机构信息
1] Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA [2] Department of Cancer Biology, University of Cincinnati, Cincinnati, OH, USA.
Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
出版信息
Leukemia. 2014 May;28(5):1142-5. doi: 10.1038/leu.2013.372. Epub 2013 Dec 11.
Abstract
摘要
相似文献
1
An MDS xenograft model utilizing a patient-derived cell line.一种利用患者来源细胞系的骨髓增生异常综合征异种移植模型。
Leukemia. 2014 May;28(5):1142-5. doi: 10.1038/leu.2013.372. Epub 2013 Dec 11.
2
Preclinical characterisation and development of a novel myelodysplastic syndrome-derived cell line.一种新型骨髓增生异常综合征衍生细胞系的临床前表征与开发
Br J Haematol. 2021 Apr;193(2):415-419. doi: 10.1111/bjh.17372. Epub 2021 Mar 9.
3
USP7 inhibition inhibits proliferation and induces megakaryocytic differentiation in MDS cells by upregulating gelsolin.USP7 抑制通过上调凝溶胶蛋白抑制 MDS 细胞的增殖并诱导巨核细胞分化。
Br J Haematol. 2020 Aug;190(3):418-429. doi: 10.1111/bjh.16549. Epub 2020 Mar 4.
4
Establishment of a myelodysplastic syndrome (MDS)/secondary AML-derived T lymphoid cell line K2-MDS.建立一种骨髓增生异常综合征（MDS）/继发性急性髓系白血病来源的T淋巴细胞系K2-MDS。
Leuk Res. 2000 Feb;24(2):103-8. doi: 10.1016/s0145-2126(99)00168-x.
5
Establishment of a Novel Myelodysplastic Syndrome (MDS) Xenotransplantation Model.新型骨髓增生异常综合征（MDS）异种移植模型的建立。
Clin Lab. 2016 Sep 1;62(9):1651-1659. doi: 10.7754/Clin.Lab.2016.160107.
6
Efficacy of the novel tubulin polymerization inhibitor PTC-028 for myelodysplastic syndrome.新型微管聚合抑制剂 PTC-028 治疗骨髓增生异常综合征的疗效。
Cancer Sci. 2020 Dec;111(12):4336-4347. doi: 10.1111/cas.14684. Epub 2020 Nov 2.
7
An accessible patient-derived xenograft model of low-risk myelodysplastic syndromes.一种可获取的低风险骨髓增生异常综合征患者来源异种移植模型。
Haematologica. 2024 Jan 1;109(1):337-342. doi: 10.3324/haematol.2023.282967.
8
The cell growth, morphology and immunocytochemistry of novel cell line established from a bone marrow of the patient with therapy-related myelodysplastic syndrome, entitled PC-MDS.从一名患有治疗相关骨髓增生异常综合征的患者骨髓中建立的名为PC-MDS的新型细胞系的细胞生长、形态学和免疫细胞化学。
Med Oncol. 2007;24(4):419-24. doi: 10.1007/s12032-007-0031-y.
9
Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.骨髓增生异常综合征/骨髓增殖性肿瘤重叠综合征患者来源的强大异种移植模型体现了慢性粒单核细胞白血病和青少年型骨髓单核细胞白血病的独特特征。
Blood. 2017 Jul 27;130(4):397-407. doi: 10.1182/blood-2017-01-763219. Epub 2017 Jun 2.
10
Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit.患者骨髓增生异常细胞重编程间充质基质细胞，建立可移植的干细胞龛疾病单元。
Cell Stem Cell. 2014 Jun 5;14(6):824-37. doi: 10.1016/j.stem.2014.02.014. Epub 2014 Apr 3.
引用本文的文献
1
Integrated cytogenetic and genomic profiling of the MDS-L cell line.骨髓增生异常综合征-L细胞系的细胞遗传学和基因组综合分析
Mol Cytogenet. 2025 Jun 11;18(1):11. doi: 10.1186/s13039-025-00714-7.
2
Splicing regulatory dynamics for precision analysis and treatment of heterogeneous leukemias.用于精准分析和治疗异质性白血病的剪接调控动力学
Sci Transl Med. 2025 May 7;17(797):eadr1471. doi: 10.1126/scitranslmed.adr1471.
3
TOPORS E3 ligase mediates resistance to hypomethylating agent cytotoxicity in acute myeloid leukemia cells.TOPORS E3 连接酶介导急性髓系白血病细胞对低甲基化药物细胞毒性的耐药性。
Nat Commun. 2024 Aug 28;15(1):7360. doi: 10.1038/s41467-024-51646-6.
4
The evolution of preclinical models for myelodysplastic neoplasms.骨髓增生异常肿瘤前临床模型的演变。
Leukemia. 2024 Apr;38(4):683-691. doi: 10.1038/s41375-024-02181-2. Epub 2024 Feb 23.
5
mutations are associated with a response to alvocidib and 5-azacytidine combination in myelodysplastic neoplasms.突变与骨髓增生异常肿瘤中阿伐麦布和 5-氮杂胞苷联合治疗的反应相关。
Haematologica. 2024 May 1;109(5):1426-1438. doi: 10.3324/haematol.2023.282921.
6
Inactivation of p53 provides a competitive advantage to del(5q) myelodysplastic syndrome hematopoietic stem cells during inflammation.在炎症期间，p53 的失活为 del(5q) 骨髓增生异常综合征造血干细胞提供了竞争优势。
Haematologica. 2023 Oct 1;108(10):2715-2729. doi: 10.3324/haematol.2022.282349.
7
CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine.CCRL2 影响骨髓增生异常综合征和继发性急性髓系白血病细胞对阿扎胞苷的敏感性。
Haematologica. 2023 Jul 1;108(7):1886-1899. doi: 10.3324/haematol.2022.281444.
8
A new software tool for computer assisted in vivo high-content analysis of transplanted fluorescent cells in intact zebrafish larvae.一种新的软件工具，用于在完整的斑马鱼幼虫中对移植的荧光细胞进行计算机辅助的体内高内涵分析。
Biol Open. 2022 Dec 15;11(12). doi: 10.1242/bio.059530. Epub 2022 Dec 13.
9
Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations.靶向炎症免疫信号的激活在携带 SF3B1 突变的骨髓增生异常综合征中可见。
Elife. 2022 Aug 30;11:e78136. doi: 10.7554/eLife.78136.
10
Selective inhibition of MCL1 overcomes venetoclax resistance in a murine model of myelodysplastic syndromes.选择性抑制 MCL1 可克服骨髓增生异常综合征小鼠模型中的 venetoclax 耐药性。
Haematologica. 2023 Feb 1;108(2):522-531. doi: 10.3324/haematol.2022.280631.
本文引用的文献
1
Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.针对 IRAK1 作为骨髓增生异常综合征的治疗方法。
Cancer Cell. 2013 Jul 8;24(1):90-104. doi: 10.1016/j.ccr.2013.05.006.
2
Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes.骨髓增生异常综合征中的造血干细胞和祖细胞机制。
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):3011-6. doi: 10.1073/pnas.1222861110. Epub 2013 Feb 6.
3
AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model.在人源异种移植模型中，AML 细胞对化疗治疗具有不同的敏感性。
Blood. 2013 Mar 21;121(12):e90-7. doi: 10.1182/blood-2012-10-464677. Epub 2013 Jan 24.
4
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.一项来那度胺对比安慰剂在 RBC 输血依赖低/中-1 风险伴 5q- 骨髓增生异常综合征患者中随机 3 期研究。
Blood. 2011 Oct 6;118(14):3765-76. doi: 10.1182/blood-2011-01-330126. Epub 2011 Jul 13.
5
AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3.在组成性表达人干细胞因子、粒细胞-巨噬细胞集落刺激因子和白细胞介素-3的NOD/SCID-IL2RG小鼠中，急性髓系白血病异种移植效率显著提高。
Leukemia. 2010 Oct;24(10):1785-8. doi: 10.1038/leu.2010.158. Epub 2010 Aug 5.
6
Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis.来那度胺通过抑制细胞分裂诱导缺失 5q 染色体的 MDS 细胞系发生细胞死亡。
Leukemia. 2010 Apr;24(4):748-55. doi: 10.1038/leu.2009.296. Epub 2010 Feb 4.
7
Hypocellular myelodysplastic syndromes: clinical and biological significance.低细胞性骨髓增生异常综合征：临床及生物学意义
Med Oncol. 2005;22(2):169-75. doi: 10.1385/MO:22:2:169.
8
Engraftment of distinct clonal MDS-derived hematopoietic precursors in NOD/SCID-beta2-microglobulin-deficient mice after intramedullary transplantation of hematopoietic and stromal cells.在进行造血细胞和基质细胞的髓内移植后，不同克隆的骨髓增生异常综合征来源的造血前体细胞在NOD/SCID-β2微球蛋白缺陷小鼠中的植入情况。
Blood. 2004 Oct 1;104(7):2202-3. doi: 10.1182/blood-2004-04-1518.
9
Engraftment of NOD/SCID-beta2 microglobulin null mice with multilineage neoplastic cells from patients with myelodysplastic syndrome.用骨髓增生异常综合征患者的多谱系肿瘤细胞移植NOD/SCID-β2微球蛋白缺陷小鼠。
Blood. 2004 Jun 1;103(11):4285-93. doi: 10.1182/blood-2003-09-3192. Epub 2004 Feb 12.
10
NOD/SCID mice transplanted with marrow from patients with myelodysplastic syndrome (MDS) show long-term propagation of normal but not clonal human precursors.移植了骨髓增生异常综合征（MDS）患者骨髓的NOD/SCID小鼠显示出正常而非克隆性人类前体细胞的长期增殖。
Leuk Res. 2003 May;27(5):425-36. doi: 10.1016/s0145-2126(02)00221-7.
Zotero 插件